meRfi®-GM
Tryptophan 2,3 Dioxygenase (TDO)
Welcome to meRfi-GM!
meRfi-GM provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.
Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.
Start your free trial and transform your understanding of the gut microbiota today!
Navigation
Contents
Tumoral immune resistance can be reversed by inhibiting tryptophan 2,3-dioxygenase (TDO). The inhibition of TDO leads to the restoration of antitumor immune responses, suggesting a potential therapeutic strategy for overcoming immune resistance in cancer.
Tryptophan 2,3 Dioxygenase (TDO) is a key enzyme in Tryptophan metabolism, initiating the kynurenine pathway (KP). This pathway primarily moderates the production of neuroactive compounds outside the central nervous system (CNS).
References:
see also:
[Morbus Parkinson / Parkinson's Disease (PD) & Tryptophan 2,3-dioxy…
References (Sources)
- Inhibition of Tryptophan-Dioxygenase Activity Increases the Antitumor Efficacy of Immune Checkpoint Inhibitors
- Reversal of tumoral immune resistance by inhibition of tryptophan 2,3 dioxygenase
- Tryptophan 2,3-Dioxygenase Expression Identified in Human Hepatocellular Carcinoma Cells and in Intratumoral Pericytes of Most Cancers
- Tryptophan 2,3-dioxygenase, a novel therapeutic target for Parkinson’s disease